Search - Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Access content directly

Filter your results

66 Results
Deposit type : Notice

Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia

Salem Bahashwan , Cécile Moluçon-Chabrot , Eric Hermet , Aurélie Ravinet , Aurore Douge et al.
American Journal of Hematology, 2019, 94 (1), pp.E32-E35. ⟨10.1002/ajh.25332⟩
Journal articles hal-01926811v1

Maladie de Gaucher

Marc Berger
4èmes Journées d’Hématologie Biologique du Grand-Est, Mar 2019, Nancy, France
Conference papers hal-02125901v1

Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity

Marc Berger , Céline Bourgne
Advances in experimental médicine and biology, 1139, pp.171-185, 2019, ⟨10.1007/978-3-030-14366-4_10⟩
Book sections hal-02301455v1

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Pedro Prata , Matthieu Resche-Rigon , Didier Blaise , Gérard Socié , Pierre-Simon Rohrlich et al.
Biology of Blood and Marrow Transplantation, 2019, 25 (9), pp.1798-1802. ⟨10.1016/j.bbmt.2019.05.013⟩
Journal articles hal-02301304v1

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Romain Guièze , Vivian Liu , Daniel Rosebrock , Alexis Jourdain , María Hernández-Sánchez et al.
Cancer Cell, 2019, 36 (4), pp.369-384.e13. ⟨10.1016/j.ccell.2019.08.005⟩
Journal articles hal-02318784v1

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Philipp Staber , Marco Herling , Mar Bellido , Eric Jacobsen , Matthew Davids et al.
Blood, 2019, 134 (14), pp.1132-1143. ⟨10.1182/blood.2019000402⟩
Journal articles hal-02318820v1

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

C. Kornauth , C. Herbaux , B. Boidol , C. Guillemette , P. Caron et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3965, 2019, Blood
Conference poster hal-02427551v1

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study

Karim Labreche , Mailys Daniau , Amit Sud , Philip J Law , Louis Royer-Perron et al.
Neuro-Oncology, 2019, 21 (8), pp.1039-1048. ⟨10.1093/neuonc/noz088⟩
Journal articles hal-02328989v1

Quelle place pour l’allogreffe à l’ère des nouvelles drogues et des nouvelles approches d’immunothérapie dans les hémopathies malignes ? (SFGM-TC)

Jacques-Olivier Bay
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France
Conference papers hal-02124755v1

Round table : impact of CAR T-cells on patient journey, local or regional organization, and follow-up

Jacques-Olivier Bay
Cell Therapy Innovation 360°, May 2019, Lyon, France
Conference papers hal-02056276v1

Accuracy of Chitotriosidase Activity and CCL18 Concentration in Assessing Type I Gaucher Disease Severity. A Systematic Review with Meta-analysis of Individual Participant Data

Tatiana Raskovalova , Patrick B. Deegan , Pramod K. Mistry , Elena Pavlova , Ruby Yang et al.
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference poster hal-02304018v1

Traitement de première ligne de la Leucémie Myéloïde Chronique dans la « vraie vie » : Données de l’Observatoire LMC

Alexandre Janel , Sandrine Saugues , C. Lambert , Hyacinthe Johnson-Ansah , Denis Guyotat et al.
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France. 25 (S1), pp.172, 2019, Hématologie
Conference poster hal-02304921v1

Arrêt des Inhibiteurs de Tyrosine Kinase (ITK) pour réponse optimale dans la LMC dans la « vraie vie » et recommandations du groupe Fi-LMC

Alexandre Janel , Sandrine Saugues , C. Lambert , Hyacinthe Johnson-Ansah , Denis Guyotat et al.
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France. 25 (S1), pp.173, 2019, Hématologie
Conference poster hal-02304953v1

Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients

Loic Ysebaert , A.S. Michallet , F. Bijou , A. Clavert , A. Quinquenel et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Conference poster hal-02427548v1

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma

Clémentine Sarkozy , Christiane Copie-Bergman , Diane Damotte , Susana Ben-Neriah , Barbara Burroni et al.
American Journal of Surgical Pathology, 2019, 43 (3), pp.341-351. ⟨10.1097/PAS.0000000000001198⟩
Journal articles hal-02055918v1

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1

Juliette Berger , Marie Vigan , Bruno Pereira , Thu Thuy Nguyen , Roseline Froissart et al.
Clinical Pharmacokinetics, 2019, 58 (4), pp.469-482. ⟨10.1007/s40262-018-0708-8⟩
Journal articles hal-02052295v1

Prévalence élevée des mutations de BTK chez les patients atteints de leucémie lymphoïde chronique (LLC) après 3 ans d’ibrutinib - Une étude de « vraie vie » du groupe FILO-LLC

A. Quinquenel , L.M. Fornecker , R. Letestu , C. Fleury , Loic Ysebaert et al.
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France. pp.23
Conference papers hal-02305156v1

Untreated patients with type 1 Gaucher disease: who are they? Resultas from the Gaucher Non-Treated study (GANT study)

Christine Serratrice , Jérôme Stirnemann , Amina Berrahal , Nadia Belmatoug , Fabrice Camou et al.
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference papers hal-02305170v1

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

Marc Berger , Bruno Pereira , Philippe Rousselot , Pascale Cony‐makhoul , Martine Gardembas et al.
British Journal of Haematology, 2019, 187 (3), pp.337-346. ⟨10.1111/bjh.16083⟩
Journal articles hal-02345944v1

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck Emmanuel Nicolini , Stéphanie Dulucq , Lisa Boureau , Pascale Cony-Makhoul , Aude Charbonnier et al.
Clinical Cancer Research, 2019, 25 (22), pp.6606-6613. ⟨10.1158/1078-0432.CCR-18-3373⟩
Journal articles hal-02374871v1

Clinical and Biological Characteristics and Outcomes of Richter Transformation: A French Multicenter Study from the Filo Group

C. Moulin , R. Morizot , T. Remen , H. Augé , F. Bouclet et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.4112, 2019, Blood
Conference poster hal-02427541v1

High‐dose therapy with autologous stem cells transplantation in Bing‐Neel syndrome: A retrospective analysis of 14 cases

Laurence Simon , Richard Lemal , Luc‐matthieu Fornecker , Olivier Tournilhac , Véronique Leblond et al.
American Journal of Hematology, 2019, 94 (9), pp.E227-E229. ⟨10.1002/ajh.25547⟩
Journal articles hal-02885345v1

Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC

Alexis Caulier , Elodie Drumez , Jordan Gauthier , Marie Robin , Didier Blaise et al.
Current Research in Translational Medicine, 2019, 67 (1), pp.8-15
Journal articles hal-02055904v1

Session 18 “General Session – Part I -REPEAT”

Jacques-Olivier Bay
1st European CAR T Cell Meeting, Feb 2019, Paris, France
Conference papers hal-02125948v1

1 an après la publication des recommandations sur l’arrêt de traitement quelle est l’attitude des professionnels de santé ?

Marc Berger
Membre du board Novartis de réflexion et d’échange, Feb 2019, Paris, France
Conference papers hal-02125982v1

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

Richard Lemal , Olivier Tournilhac
Journal for Immunotherapy of Cancer, 2019, 7 (1), pp.202. ⟨10.1186/s40425-019-0686-x⟩
Journal articles hal-02299391v1

A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency

Hélène Coignard-Biehler , Nizar Mahlaoui , Benoît Pilmis , Vincent Barlogis , Pauline Brosselin et al.
Journal of Clinical Immunology, 2019, 39 (7), pp.702-712. ⟨10.1007/s10875-019-00658-9⟩
Journal articles hal-02377907v1

Evolution des stratégies thérapeutiques de première ligne

Olivier Tournilhac
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France
Conference papers hal-02125859v1

What did intra-cellular Pk of imiglucerase teach us?

Marc Berger
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference papers hal-02124741v1

Gaucher disease: baseline preliminary data of the french eliglustat patient reported outcome study (ELIPRO)

Fabrice Camou , Francis Gaches , Bérengère Cador-Rousseau , Angela Coutinho , Nadia Belmatoug et al.
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference poster hal-02303946v1